A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples